A really interesting article published on Citeline’s TrialScope Intelligence Disclose Perspectives, resulting from an interview with Ali Pashazadeh, Treehill Partners CEO, around his presentation at Citeline’s TrialScope EXTRA conference on May 16, 2024.
Mr Pashazadeh argues that the current U.S. regulatory framework for clinical trial disclosure does not offer adequate protections for intellectual property, which results in some pharmaceutical companies flouting disclosure rules and possibly jeopardizing patient health.
This needs broadening out to a wider conversation, as it’s currently a woefully undercovered topic, and has ramifications across the whole drug development and biopharma space.
Read the full article on:
https://trialscopeintelligence.citeline.com/disclose-perspectives/DI000034